EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Johnson & Johnson's enterprise value is $447,515 Mil.
Johnson & Johnson's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $27,685 Mil. Therefore, Johnson & Johnson's EV-to-EBITDA for today is 16.16.
The historical rank and industry rank for Johnson & Johnson's EV-to-EBITDA or its related term are showing as below:
JNJ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.82 Med: 13.65 Max: 19.01
Current: 16.15
During the past 13 years, the highest EV-to-EBITDA of Johnson & Johnson was 19.01. The lowest was 8.82. And the median was 13.65.
JNJ's EV-to-EBITDA is ranked worse than 60.11% of 717
companies
in the Drug Manufacturers industry
Industry Median: 12.97
vs JNJ: 16.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-08-09), Johnson & Johnson's stock price is $170.18.
Johnson & Johnson's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $6.870. Therefore, Johnson & Johnson's PE Ratio for today is 24.77.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Johnson & Johnson EV-to-EBITDA Historical Data
The historical data trend for Johnson & Johnson's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Johnson & Johnson Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
EV-to-EBITDA
16.13
13.66
15.92
17.74
14.89
Johnson & Johnson Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
EV-to-EBITDA
15.85
15.69
14.89
16.39
16.86
Competitive Comparison
For the Drug Manufacturers - General subindustry, Johnson & Johnson's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson & Johnson EV-to-EBITDA Distribution
For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Johnson & Johnson's EV-to-EBITDA falls into.
Johnson & Johnson EV-to-EBITDA Calculation
Johnson & Johnson's EV-to-EBITDA for today is calculated as:
Johnson & Johnson's current Enterprise Value is $447,515 Mil.
Johnson & Johnson's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $27,685 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson & Johnson (NYSE:JNJ) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Johnson & Johnson's PE Ratio for today is calculated as:
Johnson & Johnson's share price for today is $170.18.
Johnson & Johnson's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.870.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Johnson & Johnson's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.02(0.01%) Volume: 5,529,651 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:JNJ has been successfully added to your 
